Repurposing Itraconazole as a Treatment for Advanced Prostate Cancer: A Noncomparative Randomized Phase II Trial in Men With Metastatic Castration-Resistant Prostate Cancer
This 2013 phase II trial evaluated the antifungal drug itraconazole as a potential therapy for chemotherapy-naïve men with metastatic castration-resistant prostate cancer (mCRPC). Forty-six patients were randomized to receive either low-dose (200 mg/day) or high-dose (600 mg/day) oral itraconazole. The primary endpoint was the 24-week prostate-specific antigen (PSA) progression-free survival
June 26, 2025
No Comments